Direct is patent protected out to about 2036.
What you are looking at — the Canadien patent allowance — is another broad patent protection for DCVax-l like technology that essentially reaches 2026, without counting any possible added extensions. That’s actually quite good for their patent family.
DCVax-l is also protected around 10 years from approval, if approved, by market exclusivity for use in glioblastoma.
Of course, manufacturing patents, like the new dendritic cell generator developed by flaskworks, might effectively expand protection for DCVax-l well beyond that.
It is more the broad nature of the Canadien patent that is most intriguing.
Market Data 
Markets 
AI
